- Home
- ZENV vs INKT Comparison
ZENV vs INKT Comparison
Compare ZENV & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | INKT |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 57.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZENV | INKT |
|---|---|---|
| Price | $0.84 | $11.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 28.5K | 10.1K |
| Earning Date | 03-16-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.80 | N/A |
| 52 Week Low | $0.75 | $6.34 |
| 52 Week High | $2.45 | $76.00 |
Technical Indicators
Market Signals| Indicator | ZENV | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 39.47 |
| Support Level | $0.75 | $10.98 |
| Resistance Level | $0.89 | $11.48 |
| Average True Range (ATR) | 0.07 | 0.41 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 56.83 | 10.93 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.